Denmark based Chr. Hansen completed the acquisition of LGG, probiotic strain, from Valio OY for 73 million Euro. Chr. Hansen is one of the key supplier of probiotics to dietary supplements, infant formula and dairy. Through the acquisition of the LGG business, the company is aimed to strengthen its microbial platform across all three categories and pursue new opportunity in dairy.

The newly acquired business includes the LGG trademarks and strain and related customer agreements, a collection of 3,200 strains and a small production site in Tikkurila, Finland which is engaged in development the LGG strain and a number of specialty strains used in dairy production, etc.

Besides, Chr. Hansen’s own BB-12 strain, the Lactobacillus rhamnosus GG (protected under the trademark LGG) claimed to be the best documented probiotic strain in the world. It has been used in food and dietary supplements since 1990 and has a proven beneficial effect on the gastrointestinal and immune system.

There is increasing demand of the nutraceuticals for the advancement of the human health and the expected a lucrative growth for the probiotics  industry. 

About Chr. Hansen 

Founded in 1874, Chr. Hansen is a bioscience company engaged in development and production of cultures, enzymes, probiotics and natural colors for a food, nutritional, pharmaceutical and agricultural verticals.  Company is one of the key supplier of probiotics to dietary supplements, infant formula and dairy, Company posted revenue of EUR 1,097 million for the financial year 2017/18. 

About Valio OY

Founded in 1905, Finland based Valio OY is a manufacturer of dairy products and one of the largest companies in Finland. Valio's products include cheese, powdered ingredients, butter, yogurt and milk.  Valio has net sales of EUR 1.7 billion and is Finland’s biggest food exporter. Valio offers its products in 60 countries has subsidiaries in Russia, Sweden, the Baltics, USA and China.